-
Bio-Thera Solutions Announces FDA Accepts Biologics License Application For BAT2506, A Proposed Biosimilar To Simponi®
16 Jul 2025 12:37 GMT
… .S. Food and Drug Administration (FDA) has accepted its … inflammatory markers. The reference medicine golimumab has been approved in … Thera).
About Intas Pharmaceuticals
Intas Pharmaceuticals is a pioneer … Being the most affordable treatment option, Intas' …
-
Golimumab Boosts Remission Rates in AxSpA
30 Jun 2025 04:34 GMT
… remission in a tight control treatment with golimumab, regardless of gut inflammation … anti-inflammatory drugs (NSAIDs) for 4 weeks and 50 mg golimumab every … sustained remission.
IN PRACTICE:
“Our trial demonstrated that sustained inactive disease …
-
Impact of Adherence to Golimumab on Disease Flares in Rheumatoid Arthritis: Results from a Canadian Observational Study
25 Jun 2025 20:02 GMT
… decided to initiate golimumab treatment prior to and … , csDMARDs and glucocorticoid medication, respectively (Table 1 … associated with adherence to pharmaceutical treatment for rheumatoid arthritis … 47;www.accessdata.fda.gov/drugsatfda_docs/label …
-
Drug-Induced Uveitis: Patterns, Pathogenesis and Clinical Implications
24 Jun 2025 14:26 GMT
… treatment.
Intravitreal Medications
Intravitreal medications are used for a variety of ocular indications. Drug … biologic immunomodulatory medications. FDA approved TNF inhibitors include infliximab, adalimumab, etanercept, golimumab, and …
-
Uveitis Treatment Market Size to Reach USD 4.69 Billion by 2032, Driven by Advancements in Biologics and Rising Prevalence of Autoimmune Disorders – SNS Insider
19 Jun 2025 13:51 GMT
… & Johnson – Simponi (golimumab), Remicade (infliximab)
UCB – … and other medications are often more … presence of key pharmaceutical and biotechnology companies. High … Trial Trends and Drug Development Pipeline
6. Competitive Landscape
7. Uveitis Treatment …
-
How to opt for potentially more affordable medications when treating some autoimmune or autoinflammatory diseases
05 Jun 2025 16:18 GMT
… any vaccines.
Also tell your doctor about all the medicines … or SIMPONI® (golimumab). Tell your doctor if you have ever … the US by AbbVie Biotechnology Ltd; Organon is … Biologics: More Treatment Choices. US Food and Drug Administration; Updated …
-
Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn’s Disease
30 May 2025 18:06 GMT
… trial,53 a fixed dose combination of guselkumab and golimumab … AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, … s disease: medical treatment. J Crohns … drugs for inflammatory bowel disease treatment-insights from phase II and III trials …
-
From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey
26 May 2025 11:06 GMT
… bDMARDs, anti-TNF (adalimumab, infliximab, golimumab, certolizumab, etanercept), anti-IL-6 … discontinuation of the drug due to side effects, patient-doctor request or … potential of personalized medicine driven by biomarkers to optimize treatment strategies is …
-
FDA Grants Ustekinumab-Aekn Interchangeability Designation for Stelara
07 May 2025 20:11 GMT
… of ustekinumab, including treatment of psoriatic arthritis, … to specialty high-cost medications.
“Interchangeability of Selarsdi … FDA, and they include AVT05, a proposed biosimilar for golimumab … Ustekinumab-aekn Receives FDA Approval. Drug Topics. April 19 …
-
Teva and Alvotech Gain FDA Interchangeability for SELARSDI Biosimilar to Stelara
06 May 2025 18:42 GMT
… S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech … U.S. Food and Drug Administration (FDA) has approved SELARSDI™ … product, including the treatment of adults and pediatric … the FDA: AVT05, a proposed biosimilar for Simponi (golimumab) and …